Author Archives: Maciej Paszkowski-Rogacz

In the human body, cells are regularly transforming to early stages of a malignancy. These neoplasms are typically recognized and eliminated by immune cells. Only neoplasms that escape from the surveillance of the immune system develop into a clinically relevant … Continue reading →

Hemophilia A (HA) is the most commonly occurring inheritable deficiency of blood coagulation. Severely affected individuals suffer frequent spontaneous haemorrhaging, which can lead to chronic painful and debilitating arthropathies, hematomas, and potentially life-threatening internal bleeding. About 50% of severe HA … Continue reading →

The Mildred Scheel Early Career Center P2 (MSNZ) is funding motivated scientists and medical doctors in translational oncology since 2019. Eleven research groups with more than 30 team members are being supported on campus so far. Five research groups are … Continue reading →

Technical University (TU) Dresden (Germany) announced today that they have entered a research collaboration and license agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, under which they will develop novel therapies by using … Continue reading →

The start-up project “RecTech” of Prof. Dr. Frank Buchholz was nominated for the prestigious BMBF GO-Bio award in 2018 comprising a funding volume of over 3 million Euros within the first three years. The high competitive award was granted for … Continue reading →